Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 6/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | PREP | P48147 | 1/20 | 0.40 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3747970 | 1.00 | HTR2C (0.43) | HTR2CNPC1RAB9ASMN1; SMN2CTRB1 | |
| SCHEMBL3738672 | 0.91 | CTRB1 (0.46) | HTR2CNPC1RAB9ASMN1; SMN2CTRB1 | |
| SCHEMBL8085847 | 0.85 | HTT (0.42) | HTR2CNPC1RAB9ASMN1; SMN2CTRB1 | |
| SCHEMBL8089110 | 0.85 | HTT (0.42) | HTR2CNPC1RAB9ASMN1; SMN2CTRB1 | |
| SCHEMBL3752920 | 0.85 | CHRM1 (0.38) | HTR2CCHRM1CHRM4CHRM5 | |
| SCHEMBL3751320 | 0.85 | CHRM1 (0.38) | HTR2CCHRM1CHRM4CHRM5 | |
| SCHEMBL3738309 | 0.85 | HTR2C (0.39) | HTR2CNPC1RAB9ASMN1; SMN2CTRB1 | |
| SCHEMBL3805515 | 0.85 | HTR2C (0.39) | HTR2CNPC1RAB9ASMN1; SMN2CTRB1 | |
| SCHEMBL11965219 | 0.82 | HTR2C (0.50) | HTR2CNPC1RAB9ASMN1; SMN2AGTR2 | |
| SCHEMBL3748640 | 0.82 | HTR3E (0.45) | HTR2CSMN1; SMN2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338450-B2 | Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors | LUPIN LIMITED (IN) | 2012-12-25 | — | — | US | disclosed |
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | LUPIN LIMITED (IN) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291020-A1 | NOVEL COMPOUNDS AS DIPEPTIDYL PEPTIDASE IV (DPP IV) INHIBITORS | DPP4, DPP7, DPP3 | HTR2C 2412/4885NPC1 1434/4885RAB9A 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.